The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade
Immune checkpoint inhibitors produce durable antitumor effects in various cancers, but not all patients respond. High tumor mutational burden (TMB) is a known predictor of clinical benefit. In this study, we focused on the MHC-I-dependent neoantigen presentation pathway to enhance predictive capabi...
Saved in:
| Main Authors: | Yuchen Zhang, Chen Yang, Yanchao Xu, Xiang Jiang, Jiajun Shi, Binghua Li, Decai Yu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2024-11-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://bjbms.org/ojs/index.php/bjbms/article/view/11069 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Calcium ion-binding genes can predict tumor mutation burden and immune checkpoint blockade response in a pan-cancer model
by: Wan-Yu Lin, et al.
Published: (2025-07-01) -
Dendritic cell effector mechanisms and tumor immune microenvironment infiltration define TLR8 modulation and PD-1 blockade
by: Daniel A. Ruiz-Torres, et al.
Published: (2024-12-01) -
An immune activator encapsulating PD-L1 siRNA for augmented immune checkpoint blockade immunotherapy through Zn2+ overload triggered pyroptosis
by: Liming Gong, et al.
Published: (2025-06-01) -
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
by: Ginette S. Santiago-Sánchez, et al.
Published: (2024-12-01) -
IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC
by: Yanan Cui, et al.
Published: (2025-07-01)